Immuno-Oncology Small Molecule Therapies
Immuno-oncology (IO) therapies have revolutionized anti-cancer therapies in the past a few years. Drugs reactivating tumor-specific immune response harness the innate power of human immune system to eradicate cancer cells while sparing toxicity on normal cells caused by traditional targeted or chemotherapies. Several therapeutic antibodies against immune checkpoint receptors and ligands, such as PD1, CTL4 and PD-L1, have demonstrated striking and durable clinical responses across many types for tumors and became billion-dollar blockbusters. At Abbisko, we are developing a pipeline of next-generation small molecule immune modulators to improve efficacy, overcoming resistance, lowering side effects, and synergizing with first generation IO agents.